Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

NCT03767322 is registered in ClinicalTrials.gov with Instituto Nacional de Cardiologia Ignacio Chavez as lead sponsor.

NCT NCT03767322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03767322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Phase
Phase 2
Overall status
Unknown status
Start date
December 5, 2018
Completion date
December 31, 2019
Enrollment
558 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

contrast-induced acute kidney injury, contrast-induced nephropathy